English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 7 March 2011, 15:00 HKT/SGT
Share:
    

Source: China Medical System Holdings Limited
China Medical System Accredited by 'China's Top 100 Potential Enterprises' by Forbes China for Two Consecutive Years

HONG KONG, Mar 7, 2011 - (ACN Newswire) - China Medical System Holdings Limited ("CMS" or the "Company", SEHK: 867), a leading China-based pharmaceutical services company focusing on the marketing, promotion and sale of prescription drugs, is pleased to announce that the Company was accredited as "China's Top 100 Potential Enterprises" among the list compiled by the Forbes China in February 2011. CMS has been selected on the list for two consecutive years.

Compiled by Forbes China, the "China's Top 100 Potential Enterprises" list focuses on the SMEs in China, and is the first ranking of its kind to cover the SMEs across all industries. This is the second consecutive year that CMS has won the coveted accolade for its outstanding business performance and contribution to the development of China's SMEs, and for its efforts to strive for excellence in its field.

About "China's Top 100 Potential Enterprises" by Forbes China
http://www.forbeschina.com/list/1008/more

Contact:
Hill and Knowlton Asia Ltd.

Crystal Yip  
Tel: +852 2894 6211 / 9720 6445
Email: crystal.yip@hillandknowlton.com.hk

James Wong
Tel: +852 2894 6216 / 9300 2263
Email: james.wong@hillandknowlton.com.hk



Topic: Awards
Source: China Medical System Holdings Limited

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

China Medical System Holdings Limited Related News
Feb 24, 2026 20:31 HKT/SGT
康哲藥業(867.HK/8A8.SG):創新藥磷酸蘆可替尼乳膏增加特應性皮炎(AD)適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:19 HKT/SGT
康哲药业(867.HK/8A8.SG):创新药磷酸芦可替尼乳膏增加特应性皮炎(AD)适应症中国上市许可申请获受理并获纳入优先审评
Jan 30, 2026 15:22 HKT/SGT
康哲藥業(867.HK/8A8.SG):磷酸蘆可替尼乳膏獲批 為中國批准的首款且唯一白癜風靶向藥
Jan 30, 2026 15:13 HKT/SGT
康哲药业(867.HK/8A8.SG):磷酸芦可替尼乳膏获批 为中国批准的首款且唯一白癜风靶向药
Dec 16, 2025 08:07 HKT/SGT
康哲藥業(867.HK/8A8.SG):創新藥口服JAK1抑制劑Povorcitinib在中國獲納入「突破性治療品種」
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575